Eblasakimab is a monoclonal antibody commercialized by Aslan Pharmaceuticals, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According to Globaldata, it is involved in 7 clinical trials, of which 4 were completed, 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Eblasakimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Eblasakimab is expected to reach an annual total of $506 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Eblasakimab Overview
eblasakimab (ASLAN-004) is under development for the treatment of allergic disease such as asthma, unspecified type-2 driven disease, chronic obstructive pulmonary disease and atopic eczema. It is administered through intravenous and subcutaneous route. The drug candidate is a monoclonal antibody act against interleukin-13 receptor alpha 1 and IL-4. It was under development for the treatment of solid tumors.
Aslan Pharmaceuticals Overview
Aslan Pharmaceuticals is a clinical-stage biotechnology company that develops novel therapeutics for various oncology diseases. The company’s pipeline products include Varlitinib, ASLAN003, ASLAN004 and ASLAN002. Its Varlitinib is a pan-HER inhibitor used for the treatment of biliary tract cancer, gastric cancer, breast cancer and colorectal cancer. Aslan Pharmaceuticals’ ASLAN003 is a DHODH inhibitor used for the treatment of acute myeloid leukemia; ASLAN004 is an IL-4/IL-13 receptor inhibitor used for the treatment of asthma and atopic dermatitis; and ASLAN002 is a RON/MET inhibitor used for the treatment of solid tumors. The company conducts regional clinical development programs across Asia. It operates its offices in Singapore, Taiwan and China. Aslan Pharmaceuticals is headquartered in Singapore city, Singapore.
The operating loss of the company was US$47.9 million in FY2022, compared to an operating loss of US$31.5 million in FY2021. The net loss of the company was US$51.4 million in FY2022, compared to a net loss of US$31.3 million in FY2021.
For a complete picture of Eblasakimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
